SCHEMBL4014975

SCHEMBL4014975

O=C(O)c1ccc(CNC(=O)c2cc(Cl)ccc2OCCc2ccccc2Cl)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.60
AKR1C3 P42330 1/20 0.48
PTGER2 P43116 2/20 0.48
KMT2A Q03164 1/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 1/20 0.48
EPHX2 P34913 3/20 0.46
MRGPRX4 Q96LA9 1/20 0.46
NR1H4 Q96RI1 3/20 0.46
NPC1 O15118 1/20 0.45
TP53 P04637 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
ATM Q13315 1/20 0.45
ADAMTS5 Q9UNA0 1/20 0.45
PTGER1 P34995 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692054 0.90 PTGER4 (0.58) PTGER4AKR1C3PTGER2KMT2AALDH1A1
SCHEMBL4014415 0.90 PTGER4 (0.64) PTGER4AKR1C3PTGER2KMT2AALDH1A1
SCHEMBL4014358 0.87 PTGER4 (0.67) PTGER4AKR1C3PTGER2KMT2AALDH1A1
SCHEMBL4013417 0.85 PTGER4 (0.76) PTGER4AKR1C3PTGER2KMT2ALMNA
SCHEMBL4013089 0.82 PTGER4 (0.55) PTGER4AKR1C3PTGER2LMNANPC1
SCHEMBL1154066 0.81 AKR1C3 (0.55) PTGER4AKR1C3KMT2ALMNANPC1
SCHEMBL2242766 0.81 PTGER4 (0.66) PTGER4AKR1C3PTGER2KMT2AALDH1A1
SCHEMBL10180681 0.79 PTGER4 (0.73) PTGER4AKR1C3PTGER2KMT2AALDH1A1
SCHEMBL4020932 0.79 AKR1C3 (0.46) PTGER4AKR1C3KMT2AALDH1A1LMNA
SCHEMBL11464602 0.78 PTGER4 (0.69) PTGER4PTGER2KMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
EP-1756043-B1 ORTHO SUBSTITUTED ARYL OR HETEROARYL AMIDE COMPOUNDS RAQUALIA PHARMA INC (JP) 2009-07-01 EP disclosed
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PFIZER, INC. 2009-02-05 US disclosed
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds PFIZER INC 2005-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250818-A1 Ortho substituted aryl or heteroaryl amide compounds OPRL1, PTGER1, OPRM1 PTGER4 19/4885AKR1C3 321/4885PTGER2 6/4885
US-20090036495-A1 Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists PTGER4, PTGER2, OPRL1 PTGER4 1/4885AKR1C3 1975/4885PTGER2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.